Vertex, Bristol-Myers to conduct phase 2 studies of VX-135 in combination with daclatasvir
The first study, which is expected to begin in the second quarter of 2013, will enroll approximately 20 non-cirrhotic, treatment-naïve people with chronic genotype 1 HCV infection. Vertex
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.